Navigation Links
Thesan Pharmaceuticals udpeger Dr. Bhaskar Chaudhuri til bestyrelsen i august 2014
Date:8/25/2014

SAN DIEGO, 25. august 2014 /PRNewswire/ -- Thesan Pharmaceuticals meddelte i dag, at firmaet udpeger Bhaskar Chaudhuri Ph.D. til bestyrelsen. Dr. Chaudhuri har mere end 25 års erfaring i ledelse inden for lægemidler, medicinsk forskning og udvikling og markedsføring i USA, EU og nye markeder. Han har ledet udviklingen og FDA-godkendelsen af flere NDA'er og ANDA'er. Senest var Dr. Chaudhuri adm. direktør for Valeant Phamaceutikals, før han blev arbejdende partner i Frazier Healthcare. Før Dr. Chaudhuri kom til Valeant var han adm. direktør for Dow Pharmaceuticals i perioden op til dette firmas opkøb af Valeant. Før Dow arbejdede Dr. Chaudhuri hos Bertek Pharmaceuticals (et datterselskab af Mylan Laboratories) som viceadm. direktør for videnskab og som direktør for dermatologiafdelingen hos Mylan Laboratories. Dr. Chaudhuri har et doktorat i fysisk farmakopé. Har er også medlem af bestyrelsen for flere lægemiddelselskaber.

"Vi er glade for at få Bhaskar i bestyrelsen på nuværende tidspunkt", sagde Gordon Foulkes, Thesan's adm. direktør. "Hans fantastiske CV inden for udvikling af dermatologimidler, hans markedsføringsekspertise og lederrolle i salget af flere dermatologiselskaber vil blive en fantastisk hjælp hos Thesan, når vi starter på at bygge et lederteam op for fremtiden".

"Jeg er helt klart beæret over at blive et medlem af Thesan-teamet", tilføjede Dr. Chaudhuri. Den aktuelle portefølje af banebrydende produkter, der ledes af et team af verdensklasse, giver Thesan grundlag for at være et ekstraordinært dermatologiselskab. Jeg ser frem til at bidrage til Thesans vækst og blive en del af en førende dermatologiorganisation".

Samtidig og i forbindelse med den nylige Serie B-finansiering vil Dr. Peter Moldt fra Novo Ventures blive det nye Novo-bestyrelsesmedlem, som repræsentant for dette firmas investering i Thesan. Dr. Moldt har masser af erfaring inden for bioteknologi og har været enten adm. direktør, produktionsdirektør eller udviklingschef i en række succesfulde selskaber, herunder Curalogic A/S, som han grundlagde og senere bragte på børsen i 2006. Dr. Moldt kom til Novo Ventures i 2009.

Om Thesan Pharmaceuticals, Inc.

Thesan er et bioteknologisk selskab, der fokuserer på udviklingen og markedsføringen af ny medicin til behandling af dermatologiske lidelser.
Flere oplysninger kan fås på: www.thesanpharma.com

Kontakt:
J. Gordon Foulkes, Ph.D.
Administrerende direktør
Thesan Pharmaceuticals, Inc.
Info@ThesanPharma.com


'/>"/>
SOURCE Thesan Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing
2. Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody
3. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
4. Global Medical Imaging Reagents (Nanoparticles, Fluorescent Proteins, Fluorescent Dyes and Probes, Radiopharmaceuticals and Quantum Dots) Market - Forecast to 2019
5. Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes
6. OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer
7. RXi Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell
8. RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars
9. Galmed Pharmaceuticals Reports First Half 2014 Financial Results
10. SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services
11. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... NeuMedics Inc. ... podium presentation at Life Science Innovation Northwest on June 2, 2016. The session begins ... NeuMedics compound and propriety microemulsion can be successfully used as a topical agent and ...
(Date:5/27/2016)... , May 27, 2016 At ... investors playing in this space know that volatility is what ... featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: ... Lpath Inc. (NASDAQ: LPTN ), and Heat Biologics ... gain access to the technical alerts for these stocks at: ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising treatments in ... the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient ... this year following FDA approval of a second application for a single patient, ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... variety of fracture-specific plating options designed to address fractures of the distal tibia ... solutions. , The Acumed Ankle Plating System 3 is composed of seven plate ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):